机译:Dupilumab在鼻息肉患者中杜帕里姆(Dupilumab)患者的疗效和安全性(Liberty NP Sinus-24和Liberty NP Sinus-52):两种多期,随机,双盲,安慰剂控制,并联 - 组3试验结果
Univ Ghent Fac Med Upper Airways Res Lab Ghent Belgium;
Eastern Virginia Med Sch Div Allergy Norfolk VA 23501 USA;
Ctr Hosp Univ Montreal Ctr Rech Montreal PQ Canada;
Univ Hosp Leuven Dept Otorhinolaryngol Head &
Neck Surg Expt Immunol Lab Leuven Belgium;
Regeneron Pharmaceut Tarrytown NY USA;
Univ Pittsburgh Med Ctr Div Sinonasal Disorders &
Allergy Dept Otolaryngol Head &
Neck Surg;
Univ Barcelona Hosp Clin IDIBAPS CIBERES Barcelona Spain;
Colorado Allergy &
Asthma Ctr Centennial CO USA;
Univ Penn Dept Otorhinolaryngol Head &
Neck Surg Div Rhinol Perelman Sch Med Philadelphia PA;
Brigham &
Womens Hosp Div Rheumatol Immunol &
Allergy 75 Francis St Boston MA 02115 USA;
Univ Queensland Fac Med Brisbane Qld Australia;
Fdn CIDEA Allergy &
Resp Res Unit Buenos Aires DF Argentina;
Guys &
St Thomas Hosp Dept Ear Nose &
Throat London England;
Charite Univ Med Berlin Dept Otorhinolaryngol Head &
Neck Surg Berlin Germany;
Humanitas Univ Clin &
Res Ctr IRCCS Personalized Med Asthma &
Allergy Milan Italy;
Univ Pisa Dept Surg Med Mol Biol &
Crit Care Pisa Italy;
Univ S Florida Div Allergy Immunol Tampa FL USA;
Acad Med Ctr Amsterdam Netherlands;
Univ Fukui Fac Med Sci Dept Otorhinolaryngol Head &
Neck Surg Fukui Japan;
Sanofi Bridgewater NJ USA;
Sanofi Bridgewater NJ USA;
Sanofi Bridgewater NJ USA;
Sanofi Bridgewater NJ USA;
Regeneron Pharmaceut Tarrytown NY USA;
Sanofi Chilly Mazarin France;
Sanofi Bridgewater NJ USA;
Sanofi Cambridge MA USA;
Regeneron Pharmaceut Tarrytown NY USA;
Regeneron Pharmaceut Tarrytown NY USA;
Sanofi Bridgewater NJ USA;
Regeneron Pharmaceut Tarrytown NY USA;
Regeneron Pharmaceut Tarrytown NY USA;
Regeneron Pharmaceut Tarrytown NY USA;
Sanofi Chilly Mazarin France;
机译:Dupilumab在鼻息肉患者中杜帕里姆(Dupilumab)患者的疗效和安全性(Liberty NP Sinus-24和Liberty NP Sinus-52):两种多期,随机,双盲,安慰剂控制,并联 - 组3试验结果
机译:Dupilumab在鼻息肉患者严重慢性鼻窦炎患者的疗效和安全性(Liberty NP Sinus-24和Liberty NP sinus-52):两种多期,随机,双盲,安慰剂控制,并联 - 组3试验结果结果( Vol 394,PG 1638,2019
机译:自由哮喘任务:第3阶段随机,双盲,安慰剂控制,并行群体研究,评价杜帕里姆采血/安全性,对患者的不受控制,中度至严重的哮喘
机译:自由性哮喘研究:3期随机双盲安慰剂对照平行组研究评估未控制中度至重度哮喘患者的Dupilumab疗效/安全性
机译:鼻息肉患者慢性鼻窦炎患者的基线特征,来自窦鼻窦群和鼻窦-52杜氏菌相3试验